Scientists have known about the connection between Tasigna and peripheral vascular disease because in 2011. The drug’s manufacturer, Novartis, became conscious of the threat at precisely the exact same moment.
Yet the firm failed to adequately warn doctors or patients, and lots of Americans have endured and lost their own lives consequently.
Recognizing Tasigna Atherosclerosis
Atherosclerosis may result in the life-threatening and irreversible health condition called peripheral vascular disease (PAD).
A peripheral arterial disease has harmful outcomes, such as insufficient blood circulation to the limbs resulting in tissue death and disease; the amputation of one or more limbs; acute cardiovascular disease; and departure.
Tasigna Infection Research
The first important peer-reviewed research which specifically analyzed Tasigna atherosclerosis was printed in the American Journal of Hematology.
Employing post-market clinical information, the analysis concluded that 25% of Tasigna patients underwent a vascular event and 16% suffered from a peripheral vascular disease.
Back in 2013 alone, two distinct Tasigna atherosclerosis research were printed, such as an overview of literature in the FDA that found a powerful link between Tasigna and atherosclerosis. To know more about Atherosclerosis you can refer to the source: Tasigna Atherosclerosis | Tasigna Peripheral Arterial Disease.
Novartis officials also have known of the danger of peripheral artery disease, Tasigna amputations, and passing yet never warned consumers or physicians in the USA.
In the USA, Novartis maintained the Tasigna threat silent and proceeded to aggressively and sometimes illegally. Countless American sufferers have been permanently damaged or lost their lives as a consequence of Novartis’ actions.